Castle Biosciences: Principal reports 4.9% stake
The reported 4.9% position falls within the stated ownership category of 5% or less.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Castle Biosciences Inc. (CSTL) common stock was the subject of an ownership report by Principal Global Investors, which reported beneficial ownership of 1,500,897 shares, or 4.9% of the class, as of September 30, 2026. Principal Global Investors reported shared voting and dispositive power over those shares and no sole voting or dispositive power. J. Markham Penrod, Chief Compliance Officer - North America, Principal Asset Management, signed the amendment.
Key Figures
Key Terms
beneficially owned financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.